^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    1d
    REALIZE: Pilot Imaging Study of Leukemia (clinicaltrials.gov)
    P1, N=60, Recruiting, University of Oklahoma | Trial completion date: Apr 2028 --> Apr 2029 | Trial primary completion date: Mar 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    1d
    Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1/2, N=40, Suspended, Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    decitabine
    1d
    BEXMAB: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=181, Active, not recruiting, Faron Pharmaceuticals Ltd | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • Clevegen (bexmarilimab)
    1d
    The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Ruijin Hospital
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    1d
    DREAMM 7: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=494, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jun 2026 --> Jun 2028
    Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    1d
    AVIFA: Action of the Vidaza on the Atrial Fibrillation (clinicaltrials.gov)
    P=N/A, N=1, Completed, Hospices Civils de Lyon | Unknown status --> Completed | N=14 --> 1
    Trial completion • Enrollment change
    |
    azacitidine
    1d
    DREAMM 7: China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=72, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jun 2026 --> Jun 2028
    Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    1d
    Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    ulixertinib (BVD-523)
    1d
    Exercise program on strength, body composition, and quality of life in children who have survived acute lymphoblastic leukaemia (ACTRN12626000507381)
    P=N/A, N=10, Completed, Anna Maria Markarian (Edith Cowan University)
    New trial • HEOR
    1d
    Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P=N/A, N=45, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Oracle: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (clinicaltrials.gov)
    P3, N=86, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion • Trial completion date
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    gemcitabine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)
    1d
    MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=302, Active, not recruiting, Janssen Research & Development, LLC | Phase classification: P1/2 --> P1 | Trial primary completion date: Nov 2021 --> Sep 2025
    Phase classification • Trial primary completion date • IO biomarker • First-in-human
    |
    Tecvayli (teclistamab-cqyv)